Progressive Relapsed Hodgkin's Lymphoma


Pass It On: July is National Leukemia and Lymphoma Awareness Month (September 1, 2016)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma (October 6, 2015)

The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma.... Continue Reading

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma (May 7, 2015)

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with  Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these... Continue Reading

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 23, 2014)

CancerConnect News: The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according... Continue Reading

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 18, 2014)

CancerConnect News:The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

Adcetris and PET-Adapted Salvage Therapy Effective in Relapsed/Refractory Hodgkin’s Lymphoma (January 6, 2014)

Patients with relapsed/refractory Hodgkin’s lymphoma who achieve complete responses after treatment with Adcetris® (brentuximab vedotin) can skip more toxic salvage therapy and proceed straight to transplant,... Continue Reading

Adcetris Improves Response Rates to ABVD in Hodgkin’s Lymphoma (January 2, 2014)

Adding Adcetris® (brentuximab vedotin) to the chemotherapy regimen ABVD produces a high complete response rate with a moderate increase in toxicity in patients with advanced Hodgkin’s lymphoma, according... Continue Reading

Adcetris Approved for Two Types of Lymphoma (August 26, 2011)

The targeted therapy Adcetris™ (brentuximab vedotin) has received accelerated approved by the US Food and Drug Administration (FDA) for the treatment of two types of lymphoma: Hodgkin lymphoma and systemic... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients.... Continue Reading

Targeted Therapy Promising for Relapsed Hodgkin Lymphoma (January 12, 2011)

In a Phase II clinical trial, three-quarters of patients with relapsed or refractory Hodgkin lymphoma responded to treatment with the investigational drug brentuximab vedotin. These results were presented... Continue Reading

Panobinostat Promising in Relapsed/Refractory Hodgkin’s Lymphoma (November 9, 2010)

An ongoing study of the experimental drug panobinostat (LBH-589) reports promising activity in heavily pretreated patients with relapsed and refractory Hodgkin’s lymphoma (HL). These findings were presented... Continue Reading

Hodgkin’s Survivors: Increased Fatigue, Cardiac, and Thyroid Complications (October 14, 2010)

According to an article published in the Annals of Oncology, survivors of Hodgkin’s lymphoma have a significantly increased rate of cardiac and thyroid complications than their siblings. In addition,... Continue Reading

Allogeneic Stem Cell Transplantation Viable for Children and Adolescents with Relapsed Hodgkin’s Lymphoma (September 24, 2009)

Children and adolescents with relapsed Hodgkin’s lymphoma respond well to allogeneic stem cell transplantation, according to the results of a study published in Blood.[1] Although children and adolescents... Continue Reading

September Is National Leukemia and Lymphoma Awareness Month (August 28, 2009)

As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment... Continue Reading

Hodgkin’s Survivors at Increased Risk of Stroke (June 24, 2009)

Patients who have been treated with radiation therapy for Hodgkin’s lymphoma have an elevated risk of stroke. These results were published in the Journal of the National Cancer Institute. Hodgkin’s... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS